Jae-Seung Kim
Directeur/Bestuurslid bij QURIENT CO., LTD.
Vermogen: 546 524 $ op 31-05-2024
Profiel
Jae-Seung Kim is currently the Director & Head-Research Center at Qurient Co., Ltd.
Previously, he worked as the Communications Director at Institut Pasteur Korea Research Foundation.
He holds a doctorate degree from The State University of New York.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
QURIENT CO., LTD.
0.66% | 19-12-2023 | 178 675 ( 0.66% ) | 546 524 $ | 31-05-2024 |
Actieve functies van Jae-Seung Kim
| Bedrijven | Functie | Begin |
|---|---|---|
| QURIENT CO., LTD. | Directeur/Bestuurslid | - |
Eerdere bekende functies van Jae-Seung Kim
| Bedrijven | Functie | Einde |
|---|---|---|
Institut Pasteur Korea Research Foundation
 Institut Pasteur Korea Research Foundation BiotechnologyHealth Technology Institut Pasteur Korea Research Foundation provides research and development for the treatment of infectious and chronic diseases. It develops a technology-based approach to therapeutic development through cellular models, high content screening and medicinal chemistry. The company was founded on December 29, 2003 and is headquartered in Seongnam, South Korea. | Investor Relations Contact | - |
Opleiding van Jae-Seung Kim
| The State University of New York | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| QURIENT CO., LTD. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Institut Pasteur Korea Research Foundation
Institut Pasteur Korea Research Foundation BiotechnologyHealth Technology Institut Pasteur Korea Research Foundation provides research and development for the treatment of infectious and chronic diseases. It develops a technology-based approach to therapeutic development through cellular models, high content screening and medicinal chemistry. The company was founded on December 29, 2003 and is headquartered in Seongnam, South Korea. | Health Technology |
